In the News... weekly basal + semaglutide, liver targeted insulin, Lance Bass educates about LADA, and more!
Diabetes Connections | Type 1 Diabetes
Release Date: 08/16/2024
Diabetes Connections | Type 1 Diabetes
Luna Diabetes is moving ahead with something completely new – automated dosing overnight for insulin pen users. This is an add-on therapy – a tiny pump designed for use only during sleep, you keep using injections during the day. Sounds like extra work and extra gear, but the people behind Luna say the benefits speak for themselves and that the idea is extremely well received. They’ve just moved into clinical trials and asking CEO John Sjolund to explain it all. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider....
info_outline In the News... World Diabetes Day, Free T1D Care(?!), More Mounjaro info, New pump system, and more!Diabetes Connections | Type 1 Diabetes
It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: World Diabetes Day roundup, existing drugs examined for T1D prevention, Blue Circle Health expands its novel T1D care model, Mounjaro studied further, Canada approves a new pumps system, and tragedy in the diabetes community. Find out more about Please visit our Sponsors & Partners - they help make the show possible! Learn more about from extreme temperatures Learn more about Drive The best way to keep up with Stacey and...
info_outline This period pad measures A1C - All about Qvin with CEO Dr. Sara NaseriDiabetes Connections | Type 1 Diabetes
Qvin is a small company intent on prioritizing women’s health. And they’re doing it in a way no one has thought to do before. They got FDA clearance to measure A1c with their patented period pads. Qvin is the first and only FDA-cleared menstrual pad scientifically proven to collect blood for lab testing. Featured in Time Magazine’s best inventions of 2024, CEO Dr. Sara Naseri tells me this is just the start of what they want to do for women’s health autonomy. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider....
info_outline One of only three NBA players EVER with T1D, Gary Forbes now inspires off the courtDiabetes Connections | Type 1 Diabetes
Living with type 1 diabetes as a professional athlete is an exercise in intense management and mental stamina. Gary Forbes did it before today’s technology – no CGMs or AID pumps, not even fast acting insulin at the start of his career! – and without a diabetes community. He’s making up for lost time with that last bit.. connecting in a way that he says has changed how he looks at T1D. Of course, we’re talking about basketball – as one of only three NBA players with type 1, Gary has a very unique perspective and a great message he’s getting out in a new comic series. This podcast...
info_outline In the News... Omnipod 5 iPhone update, Libre & Dexcom news, overnight insulin pump and more!Diabetes Connections | Type 1 Diabetes
It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: iPhone control for Omnipod 5 rolls out, Libre is approved for use in CT scans and MRIs, Dexcom files for 15 day wear, Luna nighttime pump goes to trial, iLet cell trials move forward and more! Find out more about Please visit our Sponsors & Partners - they help make the show possible! Learn more about from extreme temperatures Learn more about Drive The best way to keep up with Stacey and the show is by signing up for our weekly...
info_outline Lisa Katzenberger on 'It Belongs to the World,' Frederick Banting's Story, and Her Family’s T1D JourneyDiabetes Connections | Type 1 Diabetes
I talk to a LOT of people who have a child diagnosed with diabetes, so they decide to write a book. I don’t talk to a lot of children’s book authors who decide to write about diabetes. Lisa Katzenberger’s newest book – It Belongs to the World - is out right now and it tells the story of Frederick Banting. We talk about her family’s T1D story, why she wanted to write it, how the illustrator has a type 1 connection, and we get some insight into what it takes to go the traditional publishing route these days. This podcast is not intended as medical advice. If you have those kinds of...
info_outline Eversense 365: A deep dive into the CGM system that lasts a yearDiabetes Connections | Type 1 Diabetes
Eversense is now a 365 day continuous glucose monitor. Their ads say One Year – One CGM. Eversense is the only CGM with a sensor that sits fully under the skin – the transmitter still sits on top but you can take that on and off. Earlier this year the FDA designated the device an iCGM which means it can now work with insulin pumps. Lots of milestones here and lots of questions for Brian Hanson, President of CGM at Ascensia Diabetes Care, the company behind eversense. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care...
info_outline Schools are still pushing back on CGM. How you can help the legal fight for changeDiabetes Connections | Type 1 Diabetes
Earlier this year, it looked like a big win for parents of kids with diabetes when the DOJ ruled that CGM can be considered standard of care. Unfortunately, the lawyers fighting for families in this case tell me it’s not that simple, the Dept of Justice ruling may have to be litigated on the local levels across the country. They’re back to talk to me about what happened, what you need to know, and how you can make your issue known, if your child’s school is giving you a hard time about continuous glucose monitoring. Our guests this week are Bonnie Roswig, an attorney with a small...
info_outline In the News... Hurricane aid, Medtronic recall, Mounjaro supply update, stem cell T1D success... and more!Diabetes Connections | Type 1 Diabetes
It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: Hurricane aid for people with diabetes, Medtronic safety warning, stem cell updates for type 1, new study about teens and young adults with type 1, and Ryan Reed returns to racing. Find out more about Please visit our Sponsors & Partners - they help make the show possible! Learn more about from extreme temperatures Learn more about Drive The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:...
info_outline Mental Health and T1D – Support & Advice from a Passionate EndoDiabetes Connections | Type 1 Diabetes
We know the importance of mental health support during a type 1 diagnosis, so why isn’t there much of any? We know the answers – time, money, patient and caregiver bandwidth, but can’t we do something here? I’m talking to an endo who feels passionately that we can, and his team is trying their best in our difficult system to make a difference. He’s got actionable advice for you, even if your health care team doesn’t provide mental health resources. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Please...
info_outlineIt’s In the News! A look at the top diabetes stories and headlines happening now. Top stories this week: A weekly basal plus semaglutide is in the works, but not for the US right now, Tandem updates it's app recall, liver targeted insulin study, a weird walking story, and Lance Bass educates about LADA.
Find out more about Moms' Night Out
Please visit our Sponsors & Partners - they help make the show possible!
Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com)
Check out VIVI Cap to protect your insulin from extreme temperatures
Learn more about AG1 from Athletic Greens
Drive research that matters through the T1D Exchange
The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
Sign up for our newsletter here
Here's where to find us:
Learn more about everything at our home page www.diabetes-connections.com
Reach out with questions or comments: [email protected]
Episode transcription with links:
Hello and welcome to Diabetes Connections In the News! I’m Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now.
XX
Novo Nordisk moves ahead with a new combination: once-weekly insulin icodec and semaglutide. Called IcoSema, Novo plans to submit for approval in Europe, Canada, Japan and Australia but NOT the US.
As we told you earlier this summer, icodec – once weeky basal insulin – was not approved by the US FDA.
Semaglutide is the molecule underpinning Novo’s immensely popular GLP-1 drugs Ozempic and Wegovy. Icodec has been approved as Awiqli in places like Europe, Canada, Japan and Australia but was snubbed by the FDA last month.
The FDA has left the door open for another application, but Novo says they don’t expect to iron it out this year.
In studies, the combination worked well to lower A1C for people with type 2 and they lost weight. They also had fewer lows.
https://www.fiercepharma.com/pharma/corrected-after-icodec-rejection-novo-nordisk-wont-file-application-once-weekly-insulin-and
XX
An update from Tandm on their app recall. Back in March they notified users of the recall because of an issue that can cause rapid depletion of a user’s t:slim X2 insulin pump battery. This battery depletion can result in the pump shutting down sooner than expected, which some customers have continued to experience even after an updated version of the app was released.
Notices were emailed to impacted customers on August 9, 2024 with updated information and recommendations for helping avoid pump battery depletion. Tandem plans to release a new version of the app to address the remaining issues and will notify all users by email and app push notifications following its release.
Impacted customers in the U.S. with questions about this recall can contact the Tandem Diabetes Care Technical Support Team 24 hours a day, 7 days a week at [email protected] or (877) 801-6901.
https://www.businesswire.com/news/home/20240812040222/en/Tandem-Diabetes-Care-Provides-Update-on-March-2024-Nationwide-Recall-of-tconnect-Mobile-App-for-iOS-Devices
XX
If you are an adult who has type 1 diabetes, you may be eligible to participate in a trial examining the impact of an investigational liver-targeted insulin on blood glucose control, A1C, and nighttime lows.
This study is researching whether administering a liver-targeting insulin called HDV-L insulin (Hepatocyte-directed Vesicles-insulin lispro), will improve glycemic control.
HDV-L insulin is designed to act on the liver to enhance glucose storage and decrease the frequency of severe hypoglycemia in individuals requiring insulin. It is not currently approved for use.
For this trial, researchers are recruiting roughly 230 adults with type 1 diabetes aged 18-79 who are on multiple daily injections (MDI).
This study is recruiting in California, Colorado, Florida, Georgia, Illinois, Indiana, New York, North Carolina, Ohio, and Texas. To enroll or learn more about this study, contact Todd Hobbs, MD at Diasome Pharmaceuticals at [email protected] or call 216-780-9324.
Clinical Trials Identifier: NCT06238778
https://diatribe.org/diabetes-research/new-study-tests-liver-targeted-insulin-type-1-diabetes
XX
Sanofi is investing heavily to boost insulin production. They opened a new facility in Germany for the basal insulin Lantus and they announced they will invest over one billion dollars to expand production capacity in France.
Sanofi’s considerable investment in insulin production is especially important given that other insulin companies appear to be focusing their efforts on production of GLP-1 medications like Mounjaro and Ozempic, rather than insulin. This has left some patients worried that Novo Nordisk and Lilly will leave them behind to pursue more lucrative products for weight loss, especially after Novo Nordisk decided to discontinue the basal insulin Levemir.
https://diatribe.org/diabetes-medications/sanofi-build-new-state-art-insulin-plant
XX
Hoping to talk to Abbott and Medtronic soon about their partnership announced earlier this month. The companies announced that Abbot will create an integrated continuous glucose monitor that works only with Medtronic’s diabetes technology and be sold exclusively by Medtronic.
Along with announcing the partnership, Medtronic said Wednesday it received FDA approval for its Simplera CGM, which does not require fingersticks or overtape, unlike the company’s previous sensors.
The Simplera Sync sensor, which is designed to work with Medtronic’s automated insulin delivery algorithm, is under FDA review separately.
https://www.medtechdive.com/news/abbott-medtronic-partnership-automated-insulin-delivery/723600/
XX
Researchers have developed a novel computer algorithm that can predict various diseases like diabetes or stroke, just by analysing the colour of the human tongue with 98 per cent accuracy.
The imaging system developed by Middle Technical University (MTU) and the University of South Australia (UniSA) in Australia can diagnose conditions such as diabetes, stroke, anaemia, asthma, liver and gallbladder issues, Covid-19, and other vascular and gastrointestinal diseases.
"The colour, shape, and thickness of the tongue can reveal a litany of health conditions," said Ali Al-Naji, adjunct Associate Professor at MTU and UniSA.
The paper published in Technologies describes how the system analyses tongue colour to provide real-time diagnoses, demonstrating that AI can advance medical practices significantly.
The breakthrough was achieved through a series of experiments using 5,260 images to train machine-learning algorithms to detect tongue colour.
Researchers received 60 tongue images from two teaching hospitals in the Middle East, representing patients with diverse health conditions. The AI model matched tongue colour with the correct disease in nearly all cases.
https://www.ndtv.com/world-news/new-algorithm-analyses-tongue-to-predict-diabetes-stroke-with-98-accuracy-6327124
XX
Big roundup article from the UK Guardian all about 6 projects all around smart insulin. Not a lot new here, but it caused a lot of chatter. I’ll link it up – good summary of all of the research happening in the space right now. Glucose-responsive insulin is the idea that you could give one injection and the insulin would respond to the rise and fall of glucose levels without further action by the person.
https://www.theguardian.com/society/article/2024/aug/11/scientists-hail-smart-insulin-responds-changing-blood-sugar-levels-real-time-diabetes
XX
Edgepark Commercial
XX
Lance Bass (like glass) continues to keep the public posted on his recent LADA diagnosis. The boy band singer showing his IG audience more about what’s also called diabetes 1.5 and explaining how he was first diagnosed with type 2.
XX
Ok, brace yourself – I promise this is a real story. The Fart Walk is actually good for you. Ok.. stay with me. This is really just a great silly reframing of something we all know, and I couldn’t resist putting it in here. A wellness influencer put this out – you may have seen it – claiming the after dinner stroll can limit your risk of type 2 diabetes. A lot of studies confirm that – along with it having benefits if you already have diabetes. The flatulence part – or a release of gastric pressure – is also a known benefit of moving more after meals. So it’s funny, farts are always funny, but if it gets more people to walk after they eat I’m all for it.
https://people.com/fart-walk-benefits-what-is-it-type-2-diabetes-8694630#:~:text=Wellness%20influencer%20Mairlyn%20Smith%20has,of%20day%20you%20do%20it
XX
Join us again soon!